Published in Trends Immunol on March 26, 2008
PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol (2009) 1.56
Invariant natural killer T cells: bridging innate and adaptive immunity. Cell Tissue Res (2010) 1.25
Genetically engineered mouse models in cancer research. Adv Cancer Res (2010) 1.18
Natural killer T cells in health and disease. Front Biosci (Schol Ed) (2011) 0.94
Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood (2009) 0.94
Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants. Expert Rev Vaccines (2008) 0.86
An expanding role for apolipoprotein E in sepsis and inflammation. Am J Surg (2010) 0.82
NKT cells in sepsis. Clin Dev Immunol (2010) 0.79
Invariant NKT cells increase drug-induced osteosarcoma cell death. Br J Pharmacol (2012) 0.79
Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response. Oncoimmunology (2013) 0.76
Development of a qPCR method to rapidly assess the function of NKT cells. J Immunol Methods (2014) 0.75